4th Jun 2019 09:56
LONDON (Alliance News) - Oncimmune Holdings PLC on Tuesday reported positive top line results from its early cancer detection test in patients with lung cancer.
Oncimmune Holdings shares were trading 3.2% higher at 95.50 pence each. in early trading the stock rose as high as 100.0p per share.
The randomised controlled study, which recruited 12,210 patients across Scotland, met its primary endpoint showing that the use of EarlyCDT-Lung with subsequent X-ray and computerised tomography scan reduced the incidence of patients with late-stage lung cancer at diagnosis, compared to standard clinical practice.
The immunodiagnostics company added that preparations are underway in Scotland for the conduct of a phased population-based evaluation to assess the implications of diagnosis with EarlyCDT-Lung on survival and mortality in a real-world setting.
The initial phase is expected to recruit up to 200,000 patients, each to be tested with EarlyCDT-Lung to be supplied by Oncimmune.
Related Shares:
Oncimmune